Aug 01, 2019 11:41 JST

Source: Eisai

Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package

TOKYO, Aug 01, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it refresh its SAHNE CREAM (quasi-drug) which has been widely used as medical skin care, for the first time in 20 years, and launch at pharmacies and drug stores in Japan on today August 1, 2019.

 


SAHNE brand marks its 65th anniversary this year. Since the initial launch, SAHNE CREAM has been close to the lifestyle of women who have changed with the times. Eisai is aiming for a brand used by generations around 30's, and will respond to the today's woman needs of easy and simple care at anytime and anywhere such as at home, office, and outside by this refresh of SAHNE CREAM.

The brand name SAHNE is originated from the German word for "cream", and is named under the image of fluffy and smooth of whipped cream. SAHNE CREAM, which has been particular about skin absorbing cream, is quickly absorbing and not sticky, and can be quickly applied on hands, fingers, and whole body care such as neck, decollete, elbows, knees, and heels during housework, childcare, and work as daily care of bare skin.

Compared to the existing products, new SAHNE CREAM has refreshed with mild scent, and the design has changed based on English logo SAHNE and red, which it blends in with the everyday life of mature women while maintaining the moisture and smooth comfort ability.

Eisai is striving to deliver a rich daily life to a wider range of customers through SAHNE CREAM, and to contribute for further improvement of benefits with products and services that meet diverse needs with staying close to customers' lives.

Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
 
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
 
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
 
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
 
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
 
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
 
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
 
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
More Press release >>

Latest Press Release


More Latest Release >>